Crystalline forms of azilsartan medoxomil potassium and preparation and uses thereof

Patent metadata

Field	Value
Publication number	US-9403811-B2
Application number	US-201314371737-A
Country	US
Kind code	B2
Filing date	Jan 14, 2013
Priority date	Jan 14, 2012
Publication date	Aug 2, 2016
Grant date	Aug 2, 2016

Abstract

The present invention relates to the field of pharmaceutical chemistry. Disclosed herein is a crystalline form of azilsartan medoxomil potassium, which is substantially pure. The crystalline form is crystalline form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K or form L. The substantially pure crystalline forms of azilsartan medoxomil potassium of the invention generally have good properties such as high solubility, high bioavailability, good stability, long shelf life and good antistatic property. The crystalline forms of azilsartan medoxomil potassium generally exhibit an excellent performance in reducing clinical systolic blood pressure (SBP) and average 24-hour SBP. Disclosed herein are methods of preparing the substantially pure crystalline forms of azilsartan medoxomil potassium, pharmaceutical compositions comprising the crystalline forms, and preparation methods and uses thereof.

First claim

The invention claimed is:

1. A crystalline form of azilsartan medoxomil potassium, wherein the crystalline form is form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K or form L and wherein:
a) form A has an X-ray powder diffraction pattern comprising peaks at 7.41, 10.74, 18.19, 22.83, 23.29, 23.66 and 24.80 degrees +/−5% in term of two theta;
b) form B has an X-ray powder diffraction pattern comprising peaks at 23.01, 23.11, 26.01, and 28.32 degrees +/−5% in term of two theta;
c) form C has an X-ray powder diffraction pattern comprising peaks at 6.20 and 18.70 degrees +/−5% in term of two theta;
d) form D has an X-ray powder diffraction pattern comprising peaks at 6.18, 15.22, 18.62, 19.34, 23.54, 24.88, and 26.94 degrees +/−5% in term of two theta;
e) form E has an X-ray powder diffraction pattern comprising peaks at 6.16, 13.34, 16.22, 18.58, 19.88, 21.46, 22.86, 26.84, 28.28, and 33.62 degrees +/−5% in term of two theta;
f) form F has an X-ray powder diffraction pattern comprising peaks at 17.96, 22.52, and 23.32 degrees +/−5% in term of two theta;
g) form G has an X-ray powder diffraction pattern comprising peaks at 6.18, 13.32, 14.10, 14.44, 16.02, 17.80, 18.70, 21.30, 22.70, 22.90, 23.70, 24.38, 24.74, 26.90, 28.28, and 40.50 degrees +/−5% in term of two theta;
h) form H has an X-ray powder diffraction pattern comprising peaks at 6.18, 13.32, 14.10, 14.36, 17.34, 18.72, 22.80, 23.56, and 27.02 degrees +/−5% in term of two theta;
i) form I has an X-ray powder diffraction pattern comprising peaks at 6.06, 12.10, 13.86, 15.00, 18.72, 19.54, 21.54, 23.04, 23.88, 25.44, and 28.36 degrees +/−5% in term of two theta;
j) form J has an X-ray powder diffraction pattern comprising peaks at 13.18, 15.90, 20.18, 21.10, 22.22, 22.52, 23.24, and 23.98 degrees +/−5% in term of two theta;
k) form K has an X-ray powder diffraction pattern comprising peaks at 6.06, 12.48, 13.22, 13.92, 14.34, 14.62, 15.84, 18.60, 20.14, 20.92, 22.66, 23.66, 24.00, and 26.86 degrees +/−5% in term of two theta; or
l) form L has an X-ray powder diffraction pattern comprising peaks at 10.34, 18.26, 20.92, 22.10, and 24.06 degrees +/−5% in term of two theta.

2. The crystalline form of azilsartan medoxomil potassium of claim 1 , wherein the crystalline form is form C, wherein form C has an X-ray powder diffraction pattern comprising peaks at 6.20, 12.64, 13.36, 14.48, 16.00, 18.70, 20.30, 21.38, 22.78, 23.80, and 25.04 degrees +/−5% in term of two theta.

3. The crystalline form of azilsartan medoxomil potassium of claim 1 , wherein the crystalline form is form D, wherein form D has an X-ray powder diffraction pattern comprising peaks at 6.18, 12.14, 12.90, 14.26, 14.84, 15.22, 18.62, 19.34, 20.16, 21.62, 23.54, 24.88, and 26.94 degrees +/−5% in term of two theta.

4. The crystalline form of azilsartan medoxomil potassium of claim 1 , wherein the crystalline form is form F, wherein form F has an X-ray powder diffraction pattern comprising peaks at 5.90, 8.46, 17.26, 17.96, 19.60, 21.66, 22.52, and 23.32 degrees +/−5% in term of two theta.

5. The crystalline form of azilsartan medoxomil potassium of claim 1 , wherein the crystalline form is form H, wherein form H has an X-ray powder diffraction pattern comprising peaks at 6.18, 12.08, 13.32, 14.10, 14.36, 15.14, 15.92, 17.34, 18.02, 18.72, 19.24, 20.18, 21.68, 22.80, 23.56, 24.96, 27.02, 27.60, and 30.2 degrees +/−5% in term of two theta.

6. The crystalline form of azilsartan medoxomil potassium of claim 1 , wherein the crystalline form is form J, wherein form J has an X-ray powder diffraction pattern comprising peaks at 5.94, 9.04, 9.94, 11.46, 11.88, 13.18, 14.26, 14.58, 15.90, 17.38, 17.80, 18.10, 19.32, 20.18, 21.10, 22.22, 22.52, 23.24, 23.98, 24.96, 26.44, 27.60, and 28.30 degrees +/−5% in term of two theta.

7. The crystalline form of azilsartan medoxomil potassium of claim 1 , wherein the crystalline form is form L, wherein form L has an X-ray powder diffraction pattern comprising peaks at 10.34, 10.82, 14.52, 15.52, 17.52, 18.26, 19.00, 20.54, 20.92, 21.38, 22.10, 22.84, 23.48, 24.06, 24.36, and 25.56 degrees +/−5% in term of two theta.

8. A pharmaceutical composition comprising the crystalline form of azilsartan medoxomil potassium of claim 1 and one or more of inert excipients or carriers.

9. The composition of claim 8 , wherein the crystalline form of azilsartan medoxomil potassium is form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K or form L and wherein said crystalline form of azilsartan medoxomil potassium is substantially pure.

10. A method of treating hypertension in a patient by administering to the patient a pharmaceutically effective amount of the crystalline form of azilsartan medoxomil potassium of claim.

11. The crystalline form of azilsartan medoxomil potassium of claim 1 , wherein the crystalline form is form C, wherein form C has an X-ray powder diffraction pattern comprising peaks at 6.20, 12.64, 13.36, 14.02, 14.48, 16.00, 17.74, 18.12, 18.70, 20.30, 21.38, 22.78, 23.80, 25.04, 25.60, 27.52, 28.16, 28.32, and 31.32 degrees +/−5% in term of two theta.

12. The crystalline form of azilsartan medoxomil potassium of claim 1 , wherein the crystalline form is form C, wherein form C has an X-ray powder diffraction pattern substantially as depicted in FIG. 3 wherein the peak at 6.20 degree +/−5% in term of two theta has a relative intensity of at least about 50% with respect to the strongest peak in the X-ray powder diffraction pattern.

13. The crystalline form of azilsartan medoxomil potassium of claim 1 , wherein the crystalline form is form C, wherein form C has an X-ray powder diffraction pattern substantially as depicted in FIG. 3 wherein the peak at 6.20 degree +/−5% in term of two theta has a relative intensity of at least about 70% with respect to the strongest peak in the X-ray powder diffraction pattern.

14. The crystalline form of azilsartan medoxomil potassium of claim 1 , wherein the crystalline form is form C, wherein form C has an X-ray powder diffraction pattern substantially as depicted in FIG. 3 wherein the peak at 6.20 degree +/−5% in term of two theta has a relative intensity of at least about 90% with respect to the strongest peak in the X-ray powder diffraction pattern.

Assignees

• Sunshine Lake Pharma Co Ltd
• Ruyuan Hec Pharm Co Ltd

Inventors

• Lei Xin
• Lv Zhiqing
• Wang Tianming

Classifications

• C07D413/14 Primary

  containing three or more hetero rings · CPC title

• A61P9/12

  Antihypertensives · CPC title